Company updateOct 14, 2026Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell TherapeuticsLakefront Biotherapeutics NVCompany newsroom
Company updateOct 8, 2026Lakefront Receives Transparency Notification from Bank of AmericaLakefront Biotherapeutics NVCompany newsroom
Company updateSep 8, 2026Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceLakefront Biotherapeutics NVCompany newsroom
Company updateAug 24, 2026U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of PemphigusLakefront Biotherapeutics NVCompany newsroom
Company updateAug 24, 2026Lakefront Receives Transparency Notification from Bank of AmericaLakefront Biotherapeutics NVCompany newsroom
Company updateAug 10, 2026Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business UpdateLakefront Biotherapeutics NVCompany newsroom